Vor Biopharma (NASDAQ:VOR) Now Covered by Wells Fargo & Company

Wells Fargo & Company began coverage on shares of Vor Biopharma (NASDAQ:VOR) in a research note issued on Thursday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $30.00 price target on the stock. Wells Fargo & Company‘s price target would indicate a potential upside of 130.77% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Citigroup assumed coverage on shares of Vor Biopharma in a report on Friday, January 9th. They issued a “buy” rating and a $50.00 target price on the stock. TD Cowen began coverage on Vor Biopharma in a research report on Wednesday, December 17th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. lowered their price target on shares of Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating for the company in a research report on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, January 21st. Finally, Wedbush started coverage on shares of Vor Biopharma in a research report on Tuesday, November 25th. They issued a “neutral” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $62.11.

Vor Biopharma Stock Performance

Vor Biopharma stock opened at $13.00 on Thursday. Vor Biopharma has a 1 year low of $2.62 and a 1 year high of $65.80. The firm’s 50-day moving average is $14.36 and its 200-day moving average is $19.43. The company has a market cap of $135.33 million, a P/E ratio of -0.03 and a beta of 1.99.

Institutional Investors Weigh In On Vor Biopharma

Institutional investors and hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. acquired a new position in shares of Vor Biopharma in the 4th quarter worth $36,000. Bank of America Corp DE lifted its stake in Vor Biopharma by 679.3% during the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock valued at $232,000 after buying an additional 4,144 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of Vor Biopharma in the third quarter worth about $230,000. BNP Paribas Financial Markets increased its position in shares of Vor Biopharma by 497.3% in the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock worth $296,000 after acquiring an additional 5,058 shares in the last quarter. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of Vor Biopharma during the third quarter valued at approximately $304,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).